BNP Paribas Arbitrage SA Has $414,000 Holdings in Endo International PLC (ENDP)

BNP Paribas Arbitrage SA grew its position in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 444.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,546 shares of the company’s stock after buying an additional 42,087 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Endo International were worth $414,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ENDP. Municipal Employees Retirement System of Michigan acquired a new position in shares of Endo International during the 4th quarter worth $421,000. LS Investment Advisors LLC acquired a new position in shares of Endo International during the 4th quarter worth $59,000. Van ECK Associates Corp grew its stake in shares of Endo International by 10.8% during the 4th quarter. Van ECK Associates Corp now owns 294,120 shares of the company’s stock worth $2,147,000 after purchasing an additional 28,735 shares during the period. Tibra Equities Europe Ltd acquired a new position in shares of Endo International during the 1st quarter worth $621,000. Finally, First Quadrant L P CA grew its stake in shares of Endo International by 94.7% during the 1st quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock worth $197,000 after purchasing an additional 11,926 shares during the period. Institutional investors own 94.93% of the company’s stock.

A number of equities analysts have recently weighed in on ENDP shares. Canaccord Genuity set a $17.00 price target on shares of Endo International and gave the stock a “buy” rating in a research note on Friday, March 8th. SunTrust Banks started coverage on shares of Endo International in a research note on Tuesday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. BidaskClub raised shares of Endo International from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. ValuEngine raised shares of Endo International from a “sell” rating to a “hold” rating in a research note on Tuesday, March 12th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating on shares of Endo International in a research note on Friday, March 1st. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company. Endo International has a consensus rating of “Hold” and a consensus target price of $14.88.

Shares of NASDAQ ENDP opened at $6.52 on Friday. The stock has a market capitalization of $1.49 billion, a P/E ratio of 2.26 and a beta of 1.12. Endo International PLC has a 52 week low of $5.92 and a 52 week high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.53 EPS for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.11. The firm had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.67 EPS. Equities analysts anticipate that Endo International PLC will post 2.18 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/19/bnp-paribas-arbitrage-sa-has-414000-holdings-in-endo-international-plc-endp.html.

Endo International Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: What are gap-up stocks?

Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP) (TSE:ENL).

Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.